261 related articles for article (PubMed ID: 36093342)
1. Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.
Hannoun-Levi JM; Chand-Fouche ME; Pace-Loscos T; Gautier M; Gal J; Schiappa R; Pujol N
Clin Transl Radiat Oncol; 2022 Nov; 37():64-70. PubMed ID: 36093342
[TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
[TBL] [Abstract][Full Text] [Related]
3. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis.
Martz N; Bodokh Y; Gautier M; Thamphya B; Schiappa R; Lam Cham Kee D; Chevallier D; Hannoun A; Chand ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2021 Mar; 27():89-95. PubMed ID: 33537466
[TBL] [Abstract][Full Text] [Related]
4. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
[TBL] [Abstract][Full Text] [Related]
7. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
Boladeras A; Santorsa L; Gutierrez C; Martinez E; Pera J; Pino F; Suarez JF; Ferrer F; Díaz A; Polo A; Guedea F
Radiother Oncol; 2014 Aug; 112(2):227-32. PubMed ID: 25174299
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
11. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
12. Irradiation of localized prostate cancer in the elderly: A systematic literature review.
Marotte D; Chand-Fouche ME; Boulahssass R; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jul; 35():1-8. PubMed ID: 35492872
[TBL] [Abstract][Full Text] [Related]
13. Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results.
Lauche O; Delouya G; Taussky D; Menard C; Béliveau-Nadeau D; Hervieux Y; Larouche R; Barkati M
J Contemp Brachytherapy; 2016 Apr; 8(2):104-9. PubMed ID: 27257413
[TBL] [Abstract][Full Text] [Related]
14. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
[TBL] [Abstract][Full Text] [Related]
15. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
16. Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis.
Tamihardja J; Lutyj P; Kraft J; Lisowski D; Weick S; Flentje M; Polat B
Front Oncol; 2021; 11():764536. PubMed ID: 34900712
[TBL] [Abstract][Full Text] [Related]
17. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
18. Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.
Barbera F; Triggiani L; Buglione M; Ghirardelli P; Vitali P; Caraffini B; Borghetti P; Greco D; Bardoscia L; Pasinetti N; Costa L; Maddalo M; Ghedi B; La Face B; Magrini SM
Clin Med Insights Oncol; 2017; 11():1179554917738765. PubMed ID: 29151782
[TBL] [Abstract][Full Text] [Related]
19. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
20. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]